{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T18:43:21Z","timestamp":1769625801814,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T00:00:00Z","timestamp":1476230400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI12C0050"],"award-info":[{"award-number":["HI12C0050"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioData Mining"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13040-016-0111-7","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T01:19:22Z","timestamp":1476235162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Low-mass-ion discriminant equation (LOME) for ovarian cancer screening"],"prefix":"10.1186","volume":"9","author":[{"given":"Jun Hwa","family":"Lee","sequence":"first","affiliation":[]},{"given":"Byong Chul","family":"Yoo","sequence":"additional","affiliation":[]},{"given":"Yun Hwan","family":"Kim","sequence":"additional","affiliation":[]},{"given":"Sun-A","family":"Ahn","sequence":"additional","affiliation":[]},{"given":"Seung-Gu","family":"Yeo","sequence":"additional","affiliation":[]},{"given":"Jae Youl","family":"Cho","sequence":"additional","affiliation":[]},{"given":"Kyung-Hee","family":"Kim","sequence":"additional","affiliation":[]},{"given":"Seung Cheol","family":"Kim","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,10,12]]},"reference":[{"key":"111_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1056\/NEJMcp0901926","volume":"361","author":"DL Clarke-Pearson","year":"2009","unstructured":"Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361:170\u20137.","journal-title":"N Engl J Med"},{"key":"111_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ygyno.2013.06.029","volume":"130","author":"CJ Reade","year":"2013","unstructured":"Reade CJ, Riva JJ, et al. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013;130:674\u201381.","journal-title":"Gynecol Oncol"},{"key":"111_CR3","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1002\/cncr.28183","volume":"119","author":"KH Lu","year":"2013","unstructured":"Lu KH, Skates S, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119:3454\u201361.","journal-title":"Cancer"},{"key":"111_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.cell.2012.02.032","volume":"148","author":"RJ DeBerardinis","year":"2012","unstructured":"DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012;148:1132\u201344.","journal-title":"Cell"},{"key":"111_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/metabo3030552","volume":"3","author":"RD Beger","year":"2013","unstructured":"Beger RD. A review of applications of metabolomics in cancer. Metabolites. 2013;3:552\u201374.","journal-title":"Metabolites"},{"key":"111_CR6","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/ijc.28517","volume":"134","author":"JH Lee","year":"2014","unstructured":"Lee JH, Kim KH, et al. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening. Int J Cancer. 2014;134:1844\u201353.","journal-title":"Int J Cancer"},{"key":"111_CR7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.29010","volume":"136","author":"C Ke","year":"2015","unstructured":"Ke C, Hou Y, et al. Large-scale profiling of metabolic dysregulation in ovarian cancer. Int J Cancer. 2015;136:516\u201326.","journal-title":"Int J Cancer"},{"key":"111_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cmet.2012.09.013","volume":"16","author":"DI Benjamin","year":"2012","unstructured":"Benjamin DI, Cravatt BF, et al. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab. 2012;16:565\u201377.","journal-title":"Cell Metab"},{"key":"111_CR9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3892\/ol.2014.2214","volume":"8","author":"SC Kim","year":"2014","unstructured":"Kim SC, Kim MK, et al. Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer. Oncol Lett. 2014;8:566\u201374.","journal-title":"Oncol Lett"},{"key":"111_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2407-10-55","volume":"10","author":"BC Yoo","year":"2010","unstructured":"Yoo BC, Kong SY, et al. Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling. BMC Cancer. 2010;10:55.","journal-title":"BMC Cancer"},{"key":"111_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1021\/pr3009572","volume":"12","author":"T Zhang","year":"2013","unstructured":"Zhang T, Wu X, et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res. 2013;12:505\u201312.","journal-title":"J Proteome Res"},{"key":"111_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1530\/ERC-15-0192","volume":"22","author":"L Yuan","year":"2015","unstructured":"Yuan L, Sheng X, et al. Glutamine promotes ovarian cancer cell proliferation through the mTOR\/S6 pathway. Endocr Relat Cancer. 2015;22:577\u201391.","journal-title":"Endocr Relat Cancer"},{"key":"111_CR13","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1158\/1078-0432.CCR-14-1200","volume":"21","author":"P Korangath","year":"2015","unstructured":"Korangath P, Teo WW, et al. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clin Cancer Res. 2015;21:3263\u201373.","journal-title":"Clin Cancer Res"},{"key":"111_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.15430\/JCP.2013.18.3.221","volume":"18","author":"MH Kim","year":"2013","unstructured":"Kim MH, Kim H. Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells. J Cancer Prev. 2013;18:221\u20136.","journal-title":"J Cancer Prev"},{"key":"111_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/msb.20134892","volume":"10","author":"L Yang","year":"2014","unstructured":"Yang L, Moss T, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014;10:728.","journal-title":"Mol Syst Biol"},{"key":"111_CR16","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1172\/JCI69600","volume":"123","author":"CT Hensley","year":"2013","unstructured":"Hensley CT, Wasti AT, et al. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123:3678\u201384.","journal-title":"J Clin Invest"},{"key":"111_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.semcdb.2012.02.002","volume":"23","author":"D Daye","year":"2012","unstructured":"Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23:362\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"111_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0076-6879(07)33001-2","volume":"433","author":"M Murph","year":"2007","unstructured":"Murph M, Tanaka T, et al. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007;433:1\u201325.","journal-title":"Methods Enzymol"},{"key":"111_CR19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1055-9965.1185.13.7","volume":"13","author":"R Sutphen","year":"2004","unstructured":"Sutphen R, Xu Y, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1185\u201391.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"111_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00281-011-0290-8","volume":"34","author":"D Davalos","year":"2012","unstructured":"Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34:43\u201362.","journal-title":"Semin Immunopathol"},{"key":"111_CR21","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.7314\/APJCP.2013.14.4.2273","volume":"14","author":"XJ Li","year":"2013","unstructured":"Li XJ, Wu QF, et al. Proteomic profiling of serum from stage I lung squamous cell carcinoma patients. Asian Pac J Cancer Prev. 2013;14:2273\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"key":"111_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jpba.2012.11.017","volume":"75","author":"CL Tung","year":"2013","unstructured":"Tung CL, Lin ST, et al. Proteomics-based identification of plasma biomarkers in oral squamous cell carcinoma. J Pharm Biomed Anal. 2013;75:7\u201317.","journal-title":"J Pharm Biomed Anal"},{"key":"111_CR23","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1021\/pr100395s","volume":"9","author":"AW Winden van","year":"2010","unstructured":"van Winden AW, van den Broek I, et al. Serum degradome markers for the detection of breast cancer. J Proteome Res. 2010;9:3781\u20138.","journal-title":"J Proteome Res"}],"container-title":["BioData Mining"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13040-016-0111-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13040-016-0111-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13040-016-0111-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:47:59Z","timestamp":1718833679000},"score":1,"resource":{"primary":{"URL":"http:\/\/biodatamining.biomedcentral.com\/articles\/10.1186\/s13040-016-0111-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1186\/s13040-016-0111-7","relation":{},"ISSN":["1756-0381"],"issn-type":[{"value":"1756-0381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,12]]},"article-number":"32"}}